Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RMC-6236, RAS inhibitor
Daraxonrasib · 11 trials · 32 indications
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by Investigator.
OS is defined as the time from randomization until death from any cause.
DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by Investigator.
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR.
OS is defined as the time from randomization until death from any cause.
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by blinded independent central review (BICR)
OS is defined as the time from randomization until death from any cause.
ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Subjects who discontinue due to toxicity or clinical progression prior to post-baseline tumor assessments will be considered as non-responders.
Number of patients with AEs as assessed by CTCAE v5.
Number of patients with changes in vital signs.
Number of patients with changes in clinical laboratory test values.
Number of patients with dose limiting toxicities
Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment.
Number of participants with dose limiting toxicities
Proportion of participants who complete neoadjuvant darazonrasib therapy and then attempt surgery.
Number, type, and severity of treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities in participants receiving SNV1521 plus daraxonrasib, used to identify doses suitable for further study, classified and graded according to CTCAE v6.0 and protocol-defined DLT criteria
| Arm | Type | Description |
|---|---|---|
| Arm A: daraxonrasib + zoldonrasib | EXPERIMENTAL | combination of study drugs |
| Arm B: gemcitabine and nab-paclitaxel | EXPERIMENTAL | chemotherapy |
| Arm A: daraxonrasib | EXPERIMENTAL | study drug |
| Arm B: daraxonrasib + gemcitabine and nab-paclitaxel | EXPERIMENTAL | study drug in combination with chemotherapy |
| Arm C: gemcitabine and nab-paclitaxel | ACTIVE_COMPARATOR | SOC chemotherapy |
| daraxonrasib | EXPERIMENTAL | study drug |
| SOC Observation | NO_INTERVENTION | Patients randomized to the comparator control arm will receive SOC observation. |
| docetaxel | ACTIVE_COMPARATOR | Patients randomized to the comparator control arm will receive docetaxel as the standard of care therapy. |
| RMC-6236 | EXPERIMENTAL | Study drug |
| Investigator's choice of standard of care therapy | ACTIVE_COMPARATOR | Patients randomized to Investigator's choice of standard of care chemotherapy will receive one of the following four treatments: * Gemcitabine and nab-paclitaxel (GnP) * Oxaliplatin, leucovorin, irinotecan, and 5-FU (Modified FOLFIRINOX: mFOLFIRINOX) * Liposomal irinotecan (Nal-IRI + 5-FU/LV) * Oxaliplatin, leucovorin and 5-FU IV (FOLFOX) |
| Arm A: Daraxonrasib + Ivonescimab Combination | EXPERIMENTAL | Dose Exploration and Dose Expansion (+ Carboplatin/Cisplatin + Pemetrexed) |
| Arm B: Elironrasib + Ivonescimab Combination | EXPERIMENTAL | Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort B1 (+ daraxonrasib) and Cohort B2 (+ Carboplatin/Cisplatin + Pemetrexed). |
| Arm C: Zoldonrasib + Ivonescimab Combination | EXPERIMENTAL | Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort C1 and Cohort C2 (+ Cetuximab). |
| Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC | EXPERIMENTAL | RMC-6236 (QD) and bevacizumab with 5-fluorouracil-based regimens |
| Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC | EXPERIMENTAL | RMC-6236 (QD) and cetuximab with or without mFOLFOX6 |
| Subprotocol C: metastatic PDAC | EXPERIMENTAL | RMC-6236 (QD) and gemcitabine with nab-paclitaxel |
| Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC | EXPERIMENTAL | RMC-9805 (QD or BID) with or without RMC-6236 (QD), and bevacizumab with 5-fluorouracil- based regimens |
| Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC | EXPERIMENTAL | RMC-9805 (QD or BID) with or without RMC-6236 (QD), and cetuximab with or without mFOLFOX6 |
| Subprotocol F: RAS G12D-mutated metastatic PDAC | EXPERIMENTAL | RMC-9805 (QD or BID) with or without RMC-6236 (QD), and gemcitabine with nab-paclitaxel |
| Subprotocol G: RAS G12D-mutated metastatic CRC | EXPERIMENTAL | RMC-9805 (QD) and cetuximab with FOLFIRI |
| Experimental: RMC-6236 | EXPERIMENTAL | Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations. Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, Melanoma, gynecological cancer or other solid tumors not previously specified). RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61) |
| Cohort A Perioperative Daraxonrasib | EXPERIMENTAL | Participants receive oral daraxonrasib once daily at a predetermined dose for 6 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy. |
| Cohort B Perioperative Daraxonrasib | EXPERIMENTAL | Participants receive oral daraxonrasib once daily at a predetermined dose for 12 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy. |
| Escalation | EXPERIMENTAL | Participants in this arm will take SNV1521 by mouth together with a RAS-targeted cancer medicine. The dose of SNV1521 will be increased in small steps to find a safe and tolerable dose of the combination in people with advanced pancreatic cancer. |
| Name | Type | Description |
|---|---|---|
| daraxonrasib | DRUG | oral tablets |
| gemcitabine | DRUG | intravenous (IV) infusion |
| nab-paclitaxel | DRUG | IV infusion |
| zoldonrasib | DRUG | oral tablets |
| docetaxel | DRUG | intravenous (IV) infusion |
| RMC-6236 | DRUG | Oral Tablets |
| Irinotecan | DRUG | IV infusion |
| Liposomal irinotecan | DRUG | IV infusion |
| 5-fluorouracil | DRUG | IV infusion |
| leucovorin | DRUG | IV infusion |
| Oxaliplatin | DRUG | IV infusion |
| Elironrasib | DRUG | oral tablets |
| Ivonescimab | DRUG | IV infusion |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | DRUG | IV infusion |
| cetuximab (Cohort C2 Only) | DRUG | IV infusion |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | DRUG | IV infusion |
| Daraxonrasib (Cohort B1 only) | DRUG | oral tablets |
| mFOLFOX6 regimen | DRUG | IV infusion |
| bevacizumab | DRUG | IV infusion |
| mFOLFIRINOX regimen | DRUG | IV infusion |
| cetuximab | DRUG | IV infusion |
| RMC-9805 | DRUG | Oral Tablet |
| FOLFIRI regimen | DRUG | IV infusion |
| Surgical Resection | PROCEDURE | Protocol-planned surgery performed after neoadjuvant daraxonrasib treatment and surgical planning. |
| Adjuvant Chemotherapy | DRUG | Post-surgery chemotherapy administered per institutional standard and investigator/physician discretion. |
| Adjuvant Radiation Therapy | RADIATION | Post-surgery radiation therapy may be given with adjuvant chemotherapy according to institutional standard and investigator/physician discretion. |
| SNV1521 | DRUG | SNV1521 is an oral investigational anticancer drug. In this study, SNV1521 is administered at different dose levels together with the RAS inhibitor daraxonrasib in adults with locally advanced unresectable or metastatic pancreatic cancer. |
Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically or cytologically confirmed pancreatic adenocarcinoma, including adenosquamous carcinoma, not previously treated in the locally ad...
Daraxonrasib is an investigational small molecule RAS inhibitor being developed by Revolution Medicines, Inc. for advanced solid tumors. It is being studied in pancreatic cancer, biliary tract cancers, colorectal cancer, and non-small cell lung cancer. Daraxonrasib is also known as RMC-6236 and remains in clinical development.
Daraxonrasib is being studied for advanced solid tumors, including pancreatic cancer, biliary tract cancers, colorectal cancer, and non-small cell lung cancer. Trials include resectable pancreatic ductal adenocarcinoma, metastatic KRAS G12D-mutated pancreatic adenocarcinoma, and recurrent KRAS-mutant biliary tract cancer.
Daraxonrasib targets RAS, a protein class of signaling molecules. It is a small molecule designed to inhibit RAS. The clinical program is biomarker selected, with trials enrolling patients whose tumors carry KRAS mutations, including KRAS G12D-mutated pancreatic adenocarcinoma and KRAS-mutant biliary tract cancer.
Daraxonrasib is being developed by Revolution Medicines, Inc., which trades under the ticker RVMD. The company is running the daraxonrasib clinical program across several solid tumor indications, including pancreatic cancer and biliary tract cancers.
Daraxonrasib is in Phase 1 development overall, with additional studies at later stages. A Phase 3 trial, NCT07805954, is recruiting and evaluates zoldonrasib plus daraxonrasib versus gemcitabine and nab-paclitaxel in first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma. Daraxonrasib is investigational and not approved.
Daraxonrasib trials include NCT07898813 in resectable pancreatic ductal adenocarcinoma, NCT07805954 in first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma, NCT07793253 in recurrent KRAS-mutant biliary tract cancer, and NCT07756281, a first-in-human study with SNV1521 in advanced pancreatic cancer.
Yes, daraxonrasib is the same drug as RMC-6236. RMC-6236 is an alternative name for daraxonrasib, the investigational RAS inhibitor from Revolution Medicines, Inc. being studied in pancreatic cancer, biliary tract cancers, colorectal cancer, and non-small cell lung cancer.